The 2007 report describes the current status of HSCT activity in Europe, highlights the increasing role of allogeneic HSCT in treatment of AML and gives the first quantitative information on novel cellular therapies. In 2007, there were 25 563 first HSCTs, 10 072 allogeneic (39%), 15 491 autologous (61%) and 3606 additional transplants reported from 613 centers in 42 countries. The main indications were leukemias (8061 (32%; 89% allogeneic)); lymphomas (14 627 (57%; 89% autologous)), solid tumors (1488 (6%; 96% autologous)) and nonmalignant disorders (1302 (5%; 91% allogeneic)). Peripheral blood was the main source of stem cells for autologous HSCT (98%) and the predominant source for allogeneic HSCT (71%). Among allogeneic HSCTs, the number of unrelated donor grafts equaled the number of HLA-identical sibling donor grafts for the first time (47% each). AML was the most frequent indication for allogeneic HSCT (32% of all allogeneic HSCTs), with an increase of 247 (8%). Information on novel cellular therapies was collected for the first time; there were 212 mesenchymal SCTs and 212 HSCTs for nonhematopoietic use. The indications for the latter were cardiovascular disorders (97; 46%), neurological disorders (94; 44%) and tissue repair (21; 10%). These data illustrate the expanding role of cellular therapies.
Introduction
The annual European Group for Blood and Bone Marrow Transplantation (EBMT) activity report has become an established instrument to describe the current status of HSCT in Europe to observe trends and to monitor changes in technology use. [1] [2] [3] It serves as a basis for decision making at the individual patient level as well as for health care agencies in planning and providing the infrastructure for this complex medical technology. In addition to the general description of the number of transplants by indication, donor type and stem cell source, the report has focused each year on specific aspects. The increasing use of cord blood as a stem cell source, the change from BM to peripheral blood or the utilization and integration of unrelated donor transplants were the key topics in the past. [4] [5] [6] In the 2007 report, information on the use of novel cellular therapies was integrated for the first time. The numbers of mesenchymal SCTs and the numbers of HSCT for nonhematological indications were requested. [7] [8] [9] [10] The most striking observation in the last year was the increase of allogeneic HSCTs for the treatment of AML and myelodysplastic syndromes (MDS). More detailed information is provided on the pattern of use for this indication.
Patients and methods

Data collection and validation
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Definitions
Transplant numbers. The EBMT survey focused, as in previous years, on the number of patients treated for the first time with HSCT. 1 Information on additional transplants, for instance, a second, third or fourth HSCT in a patient with a previous HSCT was collected by disease category only for those patients with a planned double allogeneic after autologous transplants; for all other situations, this information was collected generically only. The following definitions were used: 'retransplants' (autologous or allogeneic) were defined as an unplanned HSCT for rejection or relapse after a previous HSCT; 'multiple transplants' were defined as being part of a planned double or triple autologous or allogeneic transplant protocol. Information on stem cell source was collected as BM, peripheral blood or cord blood. Any transplants with a combination of stem cell source that included cord blood were reported as cord blood HSCTs. BM and peripheral blood combinations were reported as peripheral blood HSCTs. Information on reduced-intensity conditioning (RIC) was collected as a total for each team only and not for individual transplants. Definitions for RIC HSCT followed the recently published definitions.
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Transplant rates. Transplant rates were computed as the number of HSCTs per 10 million inhabitants as defined earlier. 12 Transplant rates refer to the number of transplants in a given country compared with its own population. The survey cannot make adjustments for patients who cross borders and receive their HSCT in a foreign country. Population data were obtained from the US census office (http://www.census.gov).
Economic factors. Economic factors considered in the analysis followed previously defined rules. 12 Countries were categorized by their Gross National Income (GNI) per capita according to the World Bank definitions into high income (Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland and the United Kingdom), middle income (Bulgaria, Croatia, Hungary, Latvia, Lithuania, Poland, Romania, Russia, Serbia, Slovakia and Turkey) and low income countries (Azerbaijan, Belarus, Bosnia and Herzegovina, Macedonia and Ukraine). The latter category refers to the World Bank definition of 'lower middle income' (http://www.worldbank.org). Furthermore, the category of high income was subdivided into a very highincome group, consisting of those countries with a GNI/ capita of 440 000 per capita (Denmark, Finland, Ireland, the Netherlands, Norway, Sweden, Switzerland and the United Kingdom).
The non-European countries that traditionally participate in the EBMT activity survey (Algeria, Iran, Israel, Lebanon, Saudi Arabia, South Africa and Tunisia) are included in the overall data presentation. They were not included in the analysis on economic factors. The same applies to Iceland and Luxembourg because of some missing data over the time span.
Statistical analysis. The relation of the macroeconomic factors (GNI/capita) with transplant rates was estimated by ordinary least squares by multiple regressions to measure the coefficient of determination (r 2 ) or explanatory content. programs were, as in the previous year, multiple myeloma, non-Hodgkin's lymphoma and Hodgkin's disease. The evolution over time in the number of participating teams, numbers of allogeneic and autologous HSCTs is depicted in Figure 1 .
Results
Participating teams
Transplant rates in 2007. There were marked differences in transplant rates between European countries and countries affiliated with EBMT as presented in Figure 2 . These differences relate to all transplants ( Figure 2a) and to autologous HSCT (data not shown). The differences between Eastern and Western European countries have been reported earlier. It is interesting to note that countries with similar total transplant rates had similar transplant rates for allogeneic HSCT as well as for autologous HSCT.
Disease indications in 2007
The indications for HSCT in 2007 are listed in detail in Table 1 (89%); 'leukemias' with 8061 patients (32%), 7153 patients with allogeneic HSCTs (89%), 908 with autologous (11%) HSCTs; 'solid tumors' with 1488 patients (6%), 63 with allogeneic HSCTs (4%), 1425 with autologous HSCTs (96%); and 'nonmalignant disorders' with 1302 patients (5%), 1141 with allogeneic HSCTs (91%) and 161 with autologous HSCTs (12%). The latter, autologous HSCT for nonmalignant disorders, predominantly includes patients (150) with autoimmune disorders. An additional 85 patients (0.5%), 69 with allogeneic HSCTs and 16 with autologous HSCTs, were reported as 'other indications'.
Stem cell source in 2007
Of the 15 491 autologous first transplants, 256 (2%) were BM derived, 15 234 (98%) were from peripheral blood stem cells or from combined BM and peripheral blood stem cells and one was from autologous cord blood cells (Table 1) . Of the 10 072 allogeneic first transplants, 23% were BM, 71% were peripheral blood and 6% were cord blood transplants. This corresponds to a stable proportion of peripheral blood as stem cell source compared with the 70% in 2006. The proportion of peripheral blood as stem cell source varied depending on donor type. It was 73% for HLA-identical sibling donor transplants, 68% for unrelated donors, 74% for HSCT from other family members and 73% for twin donors. Within allogeneic HSCT, the only disease indications with more BM than peripheral blood donors as stem cell source were BM failure syndromes (51% bone marrow) and congenital disorders (59% BM). The proportion of main indications varied as well within the three stem cell sources. Nonmalignant disease represented about a quarter of all indications for BM and cord blood but only a small fraction among the peripheral blood transplants.
Donor type in 2007
For the 10 072 allogeneic first transplants, HLA-identical siblings were used as donors for 4716 (47%) of the recipients, other family members for 552 (5%) of the recipients, a syngeneic twin for 52 (1%) of the recipients and an unrelated volunteer donor for 4752 (47%) of the recipients. For the first time since the introduction of the EBMT activity survey, the proportion of unrelated donors is higher than the number of HLA-identical sibling donors.
Use of RIC in 2007
The numbers of RIC HSCT continued to increase from 3530 in 2006 to 3914 in 2007 at the same rate as allogeneic HSCT. RIC was used for 36% of all allogeneic HSCTs. This information is collected in a generic way only; no information on disease distribution is possible within the activity survey. Transplant rates for allogeneic HSCTs in AML and MDS differed significantly between participating countries (Table 2 ) and ranged from less than 5 per 10 million (several countries) to 135 per 10 million inhabitants in Belgium. Countries with high transplant rates for AML also showed high transplant rates for MDS, but transplant rates for AML did not necessarily parallel transplant rates in general (Figures 2b, c and d) . It is interesting to note that transplant rates for AML in the first CR were very homogeneous with a coefficient of variation in high-income countries of 39, indicating a consensus among the participating countries. 12 The transplant rates in highincome countries for MDS varied more with a coefficient of variation of 68; for autologous HSCT for AML (Figure 2d ), the variation was even larger with a coefficient of variation of 119.
Similarly, the coefficient of determination for GNI/ capita and transplant rates differed significantly between allogeneic and autologous HSCTs. There were 1898 patients reported as having received donor lymphocyte infusions in 2007 (Table 3) . This corresponds to about two-thirds of the number of reported patients with RIC HSCT. No information on the disease indication of those patients with donor lymphocyte infusion is available from the activity survey. For the first time since the introduction of the EBMT activity survey, additional information was collected for novel cellular therapies. [7] [8] [9] [10] They confirm the importance of donor lymphocyte infusions, which parallel the development of RIC for which therapy donor lymphocyte infusion remains an integral part of the therapeutic concept. [13] [14] [15] [16] More interesting and novel are the substantial number of mesenchymal stem cell grafts and the use of hematopoietic stem cell transplants for nonhematopoietic indications, for example, cardiovascular and neurological disorders, or for tissue repair. [8] [9] [10] No specific information was collected for the donor lymphocyte infusions and the mesenchymal stem cell grafts. It is also clear from some feedback (www. eurocet.org) that the numbers of HSCT for non-hematopoietic use as well as of mesenchymal stem cell grafts are probably larger than those reported within this survey. Such grafts are frequently performed outside the traditional hematopoietic SCT units. It will be a challenge for the scientific and political community to collaborate and to get comprehensive information on the numbers, indications and outcome of these grafts. Specifically, mesenchymal stem cells, more correctly called multipotent mesenchymal stromal cells, are being tested in various clinical settings to exploit their proposed antiproliferation and immunomodulatory properties. They are obtained by the ex vivo expansion of stromal cells from BM, cord blood, fat tissue or placenta, and the host does not require conditioning or immunosuppression. Mesenchymal stromal cells actively home to distressed tissue and act through paracrinesecreted molecules rather than by transdifferentiation. The main indications being tested are acute GVHD, myocardial infarct, critical ischemic and autoimmune disease. [16] [17] [18] [19] Of specific interest is the rapidly increasing role of allogeneic HSCT for AML and MDS. Several prospective controlled trials have confirmed better outcome with allogeneic transplants, and there is often no therapy available for disease eradication other than an allogeneic HSCT. [20] [21] [22] [23] [24] Currently available data are clear concerning an advantage for younger patients with intermediate or high-risk leukemia. The heterogeneity in use of HSCT for AML and MDS, as expressed by the r 2 analysis, and the heterogeneity in use in the first CR or at later stages of the disease clearly indicate a need for a continuous evaluation of the technology. This applies even more so for autologous HSCT for AML where the explanatory content is less than 10% (by r 2 ). Data from the survey does not indicate whether a transplant was the best therapy for the individual patient indication or not. Again, it will be the task of the working parties and the AML study groups to provide evidence on the role of HSCT in this clinical situation. Such trials have been initiated (www.ebmt.org).
It is specifically interesting to note that, for the first time since the activity survey began, the numbers of unrelated HSCT equal the number of HLA-identical sibling transplants. There are several reasons behind this development. The massive increase of unrelated donor registries has increased the likelihood of finding a well-matched unrelated donor (www.wmda.org). In addition, there is increasing evidence that the well-matched donor in certain situations might be preferable to a sibling donor, for example, in the situation of an older male patient with the choice between an older female sibling donor and a young well-matched unrelated male donor.
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The activity survey does not provide any data on outcome. It also does not provide any information either on the age or sex of the patients or on their pre-or posttransplant therapy. Even more important is that there is no information on nontransplanted patients. Even though desired, this is not the purpose of this data collection. Its key focus is the rapid dissemination of the status quo in the field of HSCT. As such, this activity survey provides a formal basis for patient counseling and health care planning in the field of SCT. 
APPENDIX 2007
List of transplant centres in 2007 (Total first HSCT (total all HSCT), N allogeneic /N autologous first HSCT)
Albania: no report Andorra: no report Armenia: no report
